



A Pfizer Company

SAFETY DATA SHEET

Revision date: 20-Sep-2016

Version: 1.2

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Linezolid Injection (Hospira, Inc.)

Trade Name: Not established

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not required

Hazard Statements: Non-hazardous in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

SAFETY DATA SHEET

Material Name: Linezolid Injection (Hospira, Inc.)
Revision date: 20-Sep-2016

Page 2 of 10
Version: 1.2

3. COMPOSITION / INFORMATION ON INGREDIENTS

| Ingredient | CAS Number | EU EINECS/ELINCS List | GHS Classification | % |
|-------------------|-------------|-----------------------|---|-----|
| Linezolid | 165800-03-3 | Not Listed | STOT RE 2 (H373) | 0.2 |
| HYDROCHLORIC ACID | 7647-01-0 | 231-595-7 | Skin Corr.1B (H314) STOT SE 3 (H335) | ** |
| Sodium chloride | 7647-14-5 | 231-598-3 | Not Listed | * |
| Sodium hydroxide | 1310-73-2 | 215-185-5 | Skin Corr.1A (H314) | ** |

| Ingredient | CAS Number | EU EINECS/ELINCS List | GHS Classification | % |
|------------------------|------------|-----------------------|--------------------|---|
| Citric acid, anhydrous | 77-92-9 | 201-069-1 | Not Listed | * |
| Dextrose | 14431-43-7 | Not Listed | Not Listed | * |

Additional Information:

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:

Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of

Exposure:

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions

None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:

None

5. FIRE FIGHTING MEASURES

Extinguishing Media:

Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion

Formation of toxic gases is possible during heating or fire.

Products:

SAFETY DATA SHEET

Material Name: Linezolid Injection (Hospira, Inc.)
Revision date: 20-Sep-2016

Page 3 of 10
Version: 1.2

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Linezolid

Pfizer OEL TWA-8 Hr: 750µg/m³

HYDROCHLORIC ACID

| | |
|--------------------------------|-----------------------|
| ACGIH Ceiling Threshold Limit: | 2 ppm |
| Australia PEAK | 5 ppm |
| | 7.5 mg/m ³ |
| Austria OEL - MAKs | 5 ppm |
| | 8 mg/m ³ |
| Belgium OEL - TWA | 5 ppm |
| | 8 mg/m ³ |
| Bulgaria OEL - TWA | 5 ppm |
| | 8.0 mg/m ³ |
| Cyprus OEL - TWA | 5 ppm |
| | 8 mg/m ³ |
| Czech Republic OEL - TWA | 8 mg/m ³ |

SAFETY DATA SHEET

Material Name: Linezolid Injection (Hospira, Inc.)
 Revision date: 20-Sep-2016

Page 4 of 10
 Version: 1.2

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

| | |
|--------------------------------|--------------------------------|
| Estonia OEL - TWA | 5 ppm 8 mg/m ³ |
| Germany - TRGS 900 - TWAs | 2 ppm 3 mg/m ³ |
| Germany (DFG) - MAK | 2 ppm 3.0 mg/m ³ |
| Greece OEL - TWA | 5 ppm 7 mg/m ³ |
| Hungary OEL - TWA | 8 mg/m ³ |
| Ireland OEL - TWAs | 5 ppm 8 mg/m ³ |
| Italy OEL - TWA | 5 ppm 8 mg/m ³ |
| Japan - OELs - Ceilings | 2 ppm 3.0 mg/m ³ |
| Latvia OEL - TWA | 5 ppm 8 mg/m ³ |
| Lithuania OEL - TWA | 5 ppm 8 mg/m ³ |
| Luxembourg OEL - TWA | 5 ppm 8 mg/m ³ |
| Malta OEL - TWA | 5 ppm 8 mg/m ³ |
| Netherlands OEL - TWA | 8 mg/m ³ |
| Poland OEL - TWA | 5 mg/m ³ |
| Portugal OEL - TWA | 5 ppm 8 mg/m ³ |
| Romania OEL - TWA | 5 ppm 8 mg/m ³ |
| Slovakia OEL - TWA | 5 ppm 8.0 mg/m ³ |
| Slovenia OEL - TWA | 5 ppm 8 mg/m ³ |
| Spain OEL - TWA | 5 ppm 7.6 mg/m ³ |
| Switzerland OEL -TWAs | 2 ppm 3.0 mg/m ³ |
| Vietnam OEL - TWAs | 5 mg/m ³ |
| Sodium chloride | |
| Latvia OEL - TWA | 5 mg/m ³ |
| Lithuania OEL - TWA | 5 mg/m ³ |
| Sodium hydroxide | |
| ACGIH Ceiling Threshold Limit: | 2 mg/m ³ |
| Australia PEAK | 2 mg/m ³ |
| Austria OEL - MAKs | 2 mg/m ³ |
| Bulgaria OEL - TWA | 2.0 mg/m ³ |
| Czech Republic OEL - TWA | 1 mg/m ³ |
| Estonia OEL - TWA | 1 mg/m ³ |
| France OEL - TWA | 2 mg/m ³ |
| Greece OEL - TWA | 2 mg/m ³ |
| Hungary OEL - TWA | 2 mg/m ³ |

SAFETY DATA SHEET

Material Name: Linezolid Injection (Hospira, Inc.)
Revision date: 20-Sep-2016

Page 5 of 10
Version: 1.2

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

| | |
|---------------------------|-----------------------|
| Japan - OELs - Ceilings | 2 mg/m ³ |
| Latvia OEL - TWA | 0.5 mg/m ³ |
| OSHA - Final PELs - TWAs: | 2 mg/m ³ |
| Poland OEL - TWA | 0.5 mg/m ³ |
| Slovakia OEL - TWA | 2 mg/m ³ |
| Slovenia OEL - TWA | 2 mg/m ³ |
| Sweden OEL - TWAs | 1 mg/m ³ |
| Switzerland OEL -TWAs | 2 mg/m ³ |

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:

Liquid

Color:

Clear, colorless

Odor:

No data available.

Odor Threshold:

No data available.

Molecular Formula:

Mixture

Molecular Weight:

Mixture

Solvent Solubility:

No data available

Water Solubility:

No data available

pH:

4.4-5.2

Melting/Freezing Point (°C):

No data available

Boiling Point (°C):

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Linezolid

Measured 6-8 Log D 0.55

Dextrose

No data available

Sodium hydroxide

No data available

HYDROCHLORIC ACID

No data available

SAFETY DATA SHEET

Material Name: Linezolid Injection (Hospira, Inc.)
Revision date: 20-Sep-2016

Page 6 of 10
Version: 1.2

9. PHYSICAL AND CHEMICAL PROPERTIES

Sodium chloride

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system the developing fetus.

Known Clinical Effects: The most common adverse effects reported with clinical use were diarrhea, nausea, rash, and vomiting. Effects on blood and blood-forming organs have also occurred.

Acute Toxicity: (Species, Route, End Point, Dose)

Linezolid

Rat (F) Oral Minimum Lethal Dose 5000 mg/kg

Rat (M) Oral Minimum Lethal Dose > 5000mg/kg

Dog Oral Minimum Lethal Dose > 2000mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

Sodium chloride

Rat Oral LD50 3000 mg/kg

SAFETY DATA SHEET

Material Name: Linezolid Injection (Hospira, Inc.)
Revision date: 20-Sep-2016

Page 7 of 10
Version: 1.2

11. TOXICOLOGICAL INFORMATION

Mouse Oral LD50 4000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Linezolid

Eye Irritation Rabbit Minimal

Skin Irritation Rabbit Minimal

Antigenicity- Passive cutaneous anaphylaxis Mouse Negative

Antigenicity- Active anaphylaxis Guinea Pig Negative

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Sodium chloride

Eye Irritation Rabbit Moderate

Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Linezolid

1 Month(s) Rat Oral 20 mg/kg/day NOAEL Blood forming organs, Blood

3 Month(s) Rat Oral 10 mg/kg/day NOAEL Blood forming organs, Blood

1 Month(s) Dog Oral 20 mg/kg/day NOAEL Blood forming organs, Blood, Gastrointestinal system

3 Month(s) Dog Oral 20 mg/kg/day NOAEL Blood forming organs, Blood, Gastrointestinal system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Linezolid

Reproductive & Fertility Rat Oral 50 mg/kg/day NOAEL Fertility

Embryo / Fetal Development Rat Oral 2.5 mg/kg/day NOAEL Fetotoxicity, Not Teratogenic

Embryo / Fetal Development Rat Oral 15 mg/kg/day NOAEL Maternal Toxicity

Embryo / Fetal Development Mouse Oral 150 mg/kg/day NOAEL Fetotoxicity, Maternal Toxicity, Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Linezolid

In Vitro Unscheduled DNA Synthesis Negative

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

In Vivo Micronucleus Mouse Negative

HYDROCHLORIC ACID

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vivo Micronucleus Rat Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

SAFETY DATA SHEET

Material Name: Linezolid Injection (Hospira, Inc.)
Revision date: 20-Sep-2016

Page 8 of 10
Version: 1.2

11. TOXICOLOGICAL INFORMATION

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Linezolid

Daphnia magna (Water Flea) OECD EC50 48 Hours > 100 mg/L
Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours > 1.4 mg/L
Anabaena flos-aquae(Cyanobacteria) Algae OECD ErC50 72 Hours 1.5 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Linezolid

Activated sludge OECD EC50 > 1000 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Linezolid

Measured 6-8 Log D 0.55

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Material Name: Linezolid Injection (Hospira, Inc.)
Revision date: 20-Sep-2016

Page 9 of 10
Version: 1.2

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Citric acid, anhydrous

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 201-069-1 |

Dextrose

| | |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | Not Listed |

Linezolid

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 4 |
| EU EINECS/ELINCS List | Not Listed |

HYDROCHLORIC ACID

| | |
|---|--------------------------|
| CERCLA/SARA 313 Emission reporting | 1.0 % |
| CERCLA/SARA Hazardous Substances and their Reportable Quantities: | 5000 lb 2270 kg |
| CERCLA/SARA - Section 302 Extremely Hazardous TPQs | 500 lb |
| CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs | 5000 lb |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 5 Schedule 6 |
| EU EINECS/ELINCS List | 231-595-7 |

Sodium chloride

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 231-598-3 |

Sodium hydroxide

| | |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
|------------------------------------|------------|

SAFETY DATA SHEET

Material Name: Linezolid Injection (Hospira, Inc.)
Revision date: 20-Sep-2016

Page 10 of 10
Version: 1.2

15. REGULATORY INFORMATION

| | |
|---|------------|
| CERCLA/SARA Hazardous Substances and their Reportable Quantities: | 1000 lb |
| California Proposition 65 | 454 kg |
| Inventory - United States TSCA - Sect. 8(b) | Not Listed |
| Australia (AICS): | Present |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Present |
| EU EINECS/ELINCS List | Schedule 5 |
| | Schedule 6 |
| | 215-185-5 |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation
Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 3 - Composition / Information on Ingredients. Updated Section 16 - Other Information.

Revision date: 20-Sep-2016
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet